Biotech Co.* (Country; Symbol) Pharma Co. (Country) Type/Product Area Terms/Details (Date)

JUNE
 
Almirall SA (Spain; LSE:OKWR) Basilea Pharmaceutica AG (Switzerland) Distribution agreement for Toctino, a once-daily oral treatment for severe chronic hand eczema unresponsive to topical corticocosteroids, in selected European markets and Mexico Basilea will be eligible for up-front and milestone payments totaling $33.3M (6/16)
 
Biovail Corp. (Canada; NYSE: BVF) Kyowa Hakko Kirin Co. Ltd. (Japan) License deal to acquire U.S. and Canadian rights to commercialize products containing istradefylline to treat Parkinson's disease BLS paid an up-front fee of $10M and could pay up to $20M in development milestones through FDA approval and up to an additional $35M in sales-based milestones; BLS also will make tiered royalty payments of up to 30% on net commercial sales (6/4)
 
Sirion Therapeutics Inc.* Bausch + Lomb Agreement acquiring U.S. rights to Zirgan, which was approved in 2009 as a topical antiviral against acute hepatic keratitis Financial terms were not disclosed (6/4)
 
Talecris Biotherapeutics Holdings Corp. (TLCR) Novartis AG (Switzerland) Co-promotion deal to jointly market and sell their respective post-exposure rabies products Financial terms were not disclosed (6/16)

Notes:
# The information in the chart does not cover agricultural agreements or those between biotech companies.
The date indicated refers to the BioWorld Today issue in which the news item can be found.
* Private companies are indicated with an asterisk. Unless otherwise noted, stock symbols listed are on the Nasdaq market.
LSE = London Stock Exchange; NYSE = New York Stock Exchange.